Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
First experience with basiliximab in pediatric liver graft recipients
Autore:
Ganschow, R; Broering, DC; Stuerenburg, I; Rogiers, X; Hellwege, HH; Burdelski, M;
Indirizzi:
Univ Hamburg Hosp, Dept Pediat, D-20246 Hamburg, Germany Univ Hamburg Hosp Hamburg Germany D-20246 diat, D-20246 Hamburg, Germany Univ Hamburg Hosp, Dept Hepatobiliary, D-20246 Hamburg, Germany Univ Hamburg Hosp Hamburg Germany D-20246 iary, D-20246 Hamburg, Germany
Titolo Testata:
PEDIATRIC TRANSPLANTATION
fascicolo: 5, volume: 5, anno: 2001,
pagine: 353 - 358
SICI:
1397-3142(200110)5:5<353:FEWBIP>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE CELLULAR REJECTION; INTERLEUKIN-2 RECEPTOR; ALLOGRAFT RECIPIENTS; INDUCTION THERAPY; TRANSPLANTATION; ANTIBODY; DACLIZUMAB; PLACEBO; TRIAL; CDNAS;
Keywords:
basiliximab; liver transplantation; children; graft rejection;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
24
Recensione:
Indirizzi per estratti:
Indirizzo: Ganschow, R Univ Hamburg Hosp, Dept Pediat Pediat Gastroenterol & Hepatol,Martinistr 52, D-20246 Hamburg, Germany Univ Hamburg Hosp Martinistr 52 Hamburg Germany D-20246 rmany
Citazione:
R. Ganschow et al., "First experience with basiliximab in pediatric liver graft recipients", PEDIAT TRAN, 5(5), 2001, pp. 353-358

Abstract

Several studies have shown a significant reduction of acute cellular graftrejection in adult liver and kidney graft recipients treated with monoclonal anti-interleukin-2 (IL-2)-receptor antibodies. The mechanism was inhibition of activated T-helper cells by blocking the alpha -chain (CD25) of the IL-2 receptor. The pilot study described here evaluated the use of basiliximab in pediatric liver transplantation (LTx), which is the first report on its use in children. Fifty-two liver-transplanted children were analyzed inthis study. A matched-pair historical control group (n=26) received cyclosporin A (CsA) and prednisolone, and patients in the basiliximab group (n=26) were treated with low-dose CsA and basiliximab (after reperfusion and on day 4 posttransplant). The incidences were compared of acute graft rejections, infectious complications, and the adverse effects of immunosuppressive medication within the first 6 months post-transplant. The incidence of acute rejection was significantly higher in the control group (61.5% vs. 11.5%,p = 0.0004). The frequency of infectious complications was similar (46. 1%vs. 53.8%). Patients in the basiliximab group showed less arterial hypertension; however, the differences were not statistically significant (30.7% vs. 7.7%, p = 0.07). Nephrotoxicity, hepatotoxicity or neurotoxicity were only seen in the control group (7.7%; 3.8%; 3.8%, respectively). Hence, the use of basiliximab in combination with CsA and steroids in pediatric liver transplant recipients is safe and reduces the incidence of acute graft rejection. Further studies are needed to confirm our preliminary results and to analyze long-term effects on post-transplant lymphoproliferative disease, chronic rejection, and patient survival.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/01/20 alle ore 18:57:58